Helixgate

Helixgate

Uncategorized

Cochrane review dismissing amyloid drugs draws immediate backlash

Published

on

A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins in the brain simply don’t work.

The meta-analysis, which compiles …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

The next phase of diabetes care

Published

on

As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is reducing everyday burdens.

Continue Reading

Uncategorized

The 5 largest IPOs in biopharma history

Published

on

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

Continue Reading

Uncategorized

Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches

Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches

Published

on

After receiving the FDA’s greenlight for Hunter syndrome drug Avlayah, Denali Therapeutics CEO Ryan Watts saw the culmination of 20 years of hard work unraveling the mysteries of the blood-brain barrier.​ ​Read More

Continue Reading
Advertisement

Trending